Tema Heart & Health ETF (NASDAQ:HRTS) Short Interest Down 40.1% in June

Tema Heart & Health ETF (NASDAQ:HRTS) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 583 shares, a drop of 40.1% from the June 15th total of 974 shares. Based on an average daily volume of 8,175 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short.

Tema Heart & Health ETF Trading Up 1.3%

HRTS traded up $0.48 during midday trading on Thursday, hitting $36.46. 1,020 shares of the company were exchanged, compared to its average volume of 6,062. The company’s 50 day simple moving average is $34.78 and its 200 day simple moving average is $34.82. The firm has a market capitalization of $54.33 million, a price-to-earnings ratio of 22.06 and a beta of 0.63. Tema Heart & Health ETF has a 1-year low of $27.24 and a 1-year high of $37.57.

Institutional Trading of Tema Heart & Health ETF

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new position in Tema Heart & Health ETF during the fourth quarter valued at approximately $27,000. JPMorgan Chase & Co. purchased a new stake in Tema Heart & Health ETF in the 2nd quarter worth approximately $63,000. Citadel Advisors LLC acquired a new stake in shares of Tema Heart & Health ETF during the 3rd quarter worth approximately $243,000. Brookstone Capital Management acquired a new stake in shares of Tema Heart & Health ETF during the 4th quarter worth approximately $364,000. Finally, Royal Bank of Canada increased its holdings in shares of Tema Heart & Health ETF by 8.8% during the 1st quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock valued at $710,000 after purchasing an additional 1,703 shares in the last quarter.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.